1248P Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis.

Authors :: Dong, X.
Jian, H.
Huang, M.
Yuan, S.
Zhu, Z.
Wu, L.
Chen, M.
Bi, N.
Pan, Y.
Wang, Y.
Lv, D.
Armenteros Monterroso, E.
Huang, X.
Liu, J.
Fu, W.
Zhao, Y.
Lu, S.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS799-S799. 1p.
Publication Year :: 2024

Subjects :: *EPIDERMAL growth factor
*COHORT analysis
*OSIMERTINIB
*CHEMORADIOTHERAPY
*NON-small-cell lung carcinoma

Full Text Access

Tools